MedTrace Logo

Transcranial Doppler Evaluation After Endovascular Thrombectomy for Acute Ischemic Stroke (PRECISE-TCD)

NCT07013396 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-07-16

No results posted yet for this study

Summary

Endovascular thrombectomy (EVT) improves outcomes in acute ischemic stroke caused by large vessel occlusion. Despite successful recanalization, early neurological deterioration (END) remains frequent and is associated with poor outcomes. Transcranial Doppler (TCD) provides noninvasive, real-time assessment of cerebral blood flow velocities and may identify hemodynamic patterns associated with deterioration after EVT. PRECISE-TCD is a prospective, single-center observational study enrolling 180-300 patients undergoing EVT for anterior circulation large vessel occlusion at a tertiary academic medical center. Serial TCD examinations are performed immediately after EVT, daily for 72 hours, and as close as possible to early neurological deterioration events or clinically indicated head CT within 72 hours. The primary outcome is the association between TCD-derived hemodynamic parameters and END within 72 hours. Secondary outcomes include NIHSS at 24 hours and discharge, discharge disposition, and modified Rankin Scale at 90 days.

Conditions

  • Anterior Cerebral Artery Syndrome
  • Anterior Cerebral Artery Stroke
  • Acute Ischemic Stroke
  • Cardioembolic Stroke
  • Vasogenic Cerebral Edema

Interventions

OTHER

Transcranial Doppler (TCD) examination

Serial non-invasive TCD monitoring will be performed as soon as possible after EVT, daily for 72 hours, and when possible, close to any neurological deterioration or head CT obtained within 72 hours after EVT. TCD parameters include PSV, EDV, MFV, and PI measured in bilateral MCA, ACA, PCA, carotid siphon, vertebrobasilar arteries, and ophthalmic artery territories. Collateralization patterns, including ACA flow reversal, ophthalmic artery flow reversal, and high-flow ACA or PCA patterns relative to MCA flow, will also be assessed.

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Aarti Sarwal · Virginia Commonwealth University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2029-08-31
Completion
2029-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07013396 on ClinicalTrials.gov